Cargando…

Impact of residential area on the management of rheumatoid arthritis patients initiating their first biologic DMARD: Results from the Ontario Best Practices Research Initiative (OBRI)

Access to care and management of Rheumatoid Arthritis (RA) patients may differ based on residential area. We described differences in the profile of patients initiating their first biologic disease modifying antirheumatic drug (bDMARD) based on their residential area type. Cross-sectional analysis o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Movahedi, Mohammad, Joshi, Raman, Rampakakis, Emmanouil, Thorne, Carter, Cesta, Angela, Sampalis, John S., Bombardier, Claire
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer Health 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6531262/ https://www.ncbi.nlm.nih.gov/pubmed/31096451 http://dx.doi.org/10.1097/MD.0000000000015517

Ejemplares similares

ACPA and RF as predictors of sustained clinical remission in patients with rheumatoid arthritis: data from the Ontario Best practices Research Initiative (OBRI)
por: Pope, Janet E, et al.
Publicado: (2018)

Impact of the COVID-19 pandemic on patients with rheumatoid arthritis: data from the Ontario Best Practices Research Initiative (OBRI)
por: Wong-Pack, Matthew, et al.
Publicado: (2023)

Late-onset rheumatoid arthritis has a similar time to remission as younger-onset rheumatoid arthritis: results from the Ontario Best Practices Research Initiative
por: Li, Xiuying, et al.
Publicado: (2022)

Correction: ACPA and RF as predictors of sustained clinical remission in patients with rheumatoid arthritis: data from the Ontario Best practices Research Initiative (OBRI)
Publicado: (2019)

Disease activity trajectories for early and established rheumatoid arthritis: Real-world data from a rheumatoid arthritis cohort
por: Movahedi, Mohammad, et al.
Publicado: (2022)

Healthcare Resource Utilization and Cost of Invasive Meningococcal Disease in Ontario, Canada
por: Rampakakis, Emmanouil, et al.
Publicado: (2019)

Discontinuation of tofacitinib and TNF inhibitors in patients with rheumatoid arthritis: analysis of pooled data from two registries in Canada
por: Movahedi, Mohammad, et al.
Publicado: (2023)

Efficacy of BIO K+ CL1285((®)) in the reduction of antibiotic-associated diarrhea – a placebo controlled double-blind randomized, multi-center study
por: Sampalis, John, et al.
Publicado: (2010)

Treatment Patterns and Costs in Biologic DMARD-Naive Patients with Rheumatoid Arthritis Initiating Etanercept or Adalimumab with or Without Methotrexate
por: Tkacz, Joseph, et al.
Publicado: (2020)

Obří urychlova museli vypnout kvůli úlomku bagety
Publicado: (2009)

Obří urychlova ástic zdolal další světový rekord
Publicado: (2009)

Ve Švýcarsku znovu spuštěn obří urychlova ástic
Publicado: (2009)

Current and Emerging DMARDs for the Treatment of Rheumatoid Arthritis
por: Mysler, Eduardo, et al.
Publicado: (2021)

Joint Estimation of Remission and Response for Methotrexate‐Based DMARD Options in Rheumatoid Arthritis: A Bivariate Network Meta‐Analysis
por: Pokharel, Gyanendra, et al.
Publicado: (2019)

4β‐Hydroxycholesterol Level in Patients With Rheumatoid Arthritis Before vs. After Initiation of bDMARDs and Correlation With Inflammatory State
por: Wollmann, BM, et al.
Publicado: (2016)

Real-world treatment persistence in patients with rheumatoid arthritis initiating DMARDs in Germany—a health insurance claims data analysis
por: Fiehn, Christoph, et al.
Publicado: (2023)

Cardiovascular risk factors are negatively associated with rheumatoid arthritis disease outcomes
por: Cui, Kangping, et al.
Publicado: (2021)

Multidrug resistance proteins and DMARD efficacy in rheumatoid arthritis
por: Jansen, G, et al.
Publicado: (2004)

Treatment of Rheumatoid Arthritis with Biologic DMARDS (Rituximab and Etanercept)
por: Gashi, Afrim A., et al.
Publicado: (2014)

Delayed conventional DMARDs therapy is effective in Rheumatoid Arthritis
por: Ahsan, Tasnim, et al.
Publicado: (2017)

Risk for infections with glucocorticoids and DMARDs in patients with rheumatoid arthritis
por: Riley, Thomas R, et al.
Publicado: (2021)

Cost-utility analysis of biologic disease-modifying antirheumatic drugs (bDMARDs), targeted synthetic DMARDs (tsDMARDs) and biosimilar DMARDs (bsDMARDs) combined with methotrexate for Thai rheumatoid arthritis patients with high disease activity
por: Prawjaeng, Juthamas, et al.
Publicado: (2023)

Obří urychlovač částic CERN poběží až v roce 2010
Publicado: (2009)

Green Logistics and Health in OBRI Economies: Does Social Marketing Matter?
por: Zhang, Lingyun, et al.
Publicado: (2022)

Patient, Rheumatologist and Therapist Perspectives on the Implementation of an Allied Health Rheumatology Triage (AHRT) Initiative in Ontario Rheumatology Clinics
por: Fullerton, Laura M, et al.
Publicado: (2020)

Post Hoc Analysis of the CONFIDENCE II, PROTECT I, SHAKE THE HABIT I and SHAKE THE HABIT II Observational Studies in Mild to Moderate Hypertensive Patients Treated with Perindopril and Atorvastatin Concomitantly
por: Sampalis, John S., et al.
Publicado: (2018)

Biomarkers to Predict DMARDs Efficacy and Adverse Effect in Rheumatoid Arthritis
por: Wei, Kai, et al.
Publicado: (2022)

Rheumatoid Arthritis and Malignancy: What Should We Do With DMARDs?
por: Jeon, Chan Hong
Publicado: (2022)

Baseline factors predicting change from the initial DMARD treatment during the first 2 years of rheumatoid arthritis: experience in the ERAN inception cohort
por: McWilliams, Daniel F, et al.
Publicado: (2013)

Early DAS response after DMARD-start increases probability of achieving sustained DMARD-free remission in rheumatoid arthritis
por: Verstappen, M., et al.
Publicado: (2020)

Are DMARDs enough to prevent surgery in rheumatoid hands?
por: Sim, Yeap Swan
Publicado: (2015)

Effectiveness and tolerability of ezetimibe co-administered with statins versus statin dose-doubling in high-risk patients with persistent hyperlipidemia: The EZE(STAT)2 trial
por: Shekhar Pandey, A., et al.
Publicado: (2011)

Vědci spustili obří urychlovač částic a chtějí objasnit vznik vesmíru
Publicado: (2008)

Evropští vědci spustili po trnáctiměsí ní odstávce obří urychlova ástic
Publicado: (2009)

Biologic DMARDs and targeted synthetic DMARDs and the risk of all-cause mortality in rheumatoid arthritis: A systematic review and meta-analysis
por: Pang, Mengduan, et al.
Publicado: (2022)

The supplementary therapeutic DMARD role of low-dose glucocorticoids in rheumatoid arthritis
por: Cutolo, Maurizio, et al.
Publicado: (2014)

Healthcare professionals’ perceptions on barriers and facilitators to DMARD use in rheumatoid arthritis
por: Voshaar, M. J. H., et al.
Publicado: (2022)

Comparing cost-utility of DMARDs in autoantibody-negative rheumatoid arthritis patients
por: Nathalie, Luurssen-Masurel, et al.
Publicado: (2021)

Unraveling heterogeneity within ACPA-negative rheumatoid arthritis: the subgroup of patients with a strong clinical and serological response to initiation of DMARD treatment favor disease resolution
por: Verstappen, M., et al.
Publicado: (2022)

Obří urychlovač částic LHC bude znovu spuštěn až na jaře 2009
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_75kg1qvoc2rno5omjt9ol6usjq